EZH2 and cancer: SETD2, an upstream regulator of EZH2, can also be targeted to combat EZH2-high tumors.496 Future preclinical and clinical investigations may identify novel drug targets and formats, and will provide more insight into the value of PRC2 inhibition in cancer immunotherapy.